George Robinson

    George is a Board Observer. He is is the founding partner of Oxford Investment Consultants which advises on investments in spin-out companies from Oxford and other UK universities. He is an active investor in early stage technology and biotech companies with a particular focus on Oxford spin-outs, and was a founding investor and former board member of Adaptimmune Therapeutics (NASDAQ: $ADAP) and Immunocore (NASDAQ: $IMCR). He is also a Partner of Technikos, a private equity partnership which invests in spinout companies from the Oxford Institute of Biomedical Engineering.

    In 1993 he co-founded Sloane Robinson LLP, an investment management business which invests in listed equities globally, with a particular focus on Asian and Emerging Markets. Prior to this he worked for 15 years in Asia, initially for John Swire and Sons and then for Asian-based stockbroker WI Carr (Far East) in Korea, Thailand and Hong Kong where he was Director of Regional Research.

    George is an honorary fellow of Keble College, Oxford where he graduated with a BA in Engineering Science, and is a former-member of Oxford University Endowment Management’s Investment Committee.

    Join Replay

    Help us to author the future of genomic medicine